261 related articles for article (PubMed ID: 2126912)
1. [Clinical phase I and phase II study on a sustained release formulation of leuprorelin acetate (TAP-144-SR), an LH-RH agonist, in patients with prostatic carcinoma. Collaborative++ Studies on Prostatic Carcinoma by the Study Group for TAP-144-SR].
Niijima T; Aso Y; Akaza H; Fujita K; Fuse H; Hosaka M; Isurugi K; Kamidono S; Katayama T; Kawabe K
Hinyokika Kiyo; 1990 Nov; 36(11):1343-60. PubMed ID: 2126912
[TBL] [Abstract][Full Text] [Related]
2. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group.
Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T
Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166
[TBL] [Abstract][Full Text] [Related]
3. [Clinical phase III study on TAP-144-SR, an LH-RH agonist depot formulation, in patients with prostatic cancer].
Aso Y; Kameyama S; Niijima T; Ohmori H; Ohashi T; Murahashi I; Akimoto M; Koiso K; Akaza H; Hosaka M
Hinyokika Kiyo; 1991 Mar; 37(3):305-20. PubMed ID: 1906239
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
[TBL] [Abstract][Full Text] [Related]
5. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Akaza H; Naito S; Usami M; Tsukamoto T; Shimazaki J; Kotake T; Yamanaka H; Oohashi Y; Yoshinaka R; Onouchi H; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):781-95. PubMed ID: 12613016
[TBL] [Abstract][Full Text] [Related]
6. [Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients].
Koiso K; Yamanaka H; Ito K; Yoshinaka R; Uchida S; Yokokawa K
Hinyokika Kiyo; 2002 Dec; 48(12):771-9. PubMed ID: 12613015
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
[TBL] [Abstract][Full Text] [Related]
8. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
[TBL] [Abstract][Full Text] [Related]
9. [A new LH-RH agonist for treatment of prostate cancer, 3-month controlled-release formulation of goserelin acetate (Zoladex LA 10.8 mg depot)--outline of pre-clinical and clinical studies].
Tsukagoshi S
Gan To Kagaku Ryoho; 2002 Sep; 29(9):1675-87. PubMed ID: 12355959
[TBL] [Abstract][Full Text] [Related]
10. [A dose-comparative study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
Gan To Kagaku Ryoho; 1995 Mar; 22(4):477-94. PubMed ID: 7887640
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
12. [Long-term clinical study on TAP-144-SR, an LH-RH agonist depot formulation, in premenopausal patients with advanced or recurrent breast cancer. TAP-144-SR Breast Cancer Study Group].
Taguchi T; Koyama H; Yayoi K; Wada T; Takatsuka Y; Sonoo H; Morimoto K; Tominaga T; Abe R; Enomoto K
Gan To Kagaku Ryoho; 1995 Mar; 22(4):495-508. PubMed ID: 7887641
[TBL] [Abstract][Full Text] [Related]
13. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
[TBL] [Abstract][Full Text] [Related]
14. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
15. Leuprorelin acetate depot: results of a multicentre Japanese trial. TAP-144-SR Study Group.
Akaza H; Aso Y; Koiso K; Fuse H; Isurugi K; Okada K; Usami M; Kotake T; Ohashi T; Ueda T
J Int Med Res; 1990; 18 Suppl 1():90-102. PubMed ID: 2108889
[TBL] [Abstract][Full Text] [Related]
16. [Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].
Kotake T; Akaza H; Usami M; Naito S; Kanetake H; Taguchi T; Tsukagoshi S; Koiso K
Hinyokika Kiyo; 2001 May; 47(5):349-61. PubMed ID: 11433759
[TBL] [Abstract][Full Text] [Related]
17. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of synthetic agonist analogue of gonadotropin-releasing hormone (leuprolide) on testicular androgen production in patients with carcinoma of prostate.
Santen RJ; Warner B
Urology; 1985 Feb; 25(2 Suppl):53-7. PubMed ID: 3918377
[TBL] [Abstract][Full Text] [Related]
19. [A phase II pharmacological study of leuprolide acetate 6-month depot, TAP-144-SR (6M), in treatment-Nazve patients with prostatic cancer who received a single subcutaneous or intramuscular injection].
Komura E; Fujimoto T; Takabayashi N; Okamoto H; Akaza H
Gan To Kagaku Ryoho; 2014 May; 41(5):587-93. PubMed ID: 24917003
[TBL] [Abstract][Full Text] [Related]
20. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
